You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

CLINICAL TRIALS PROFILE FOR PERTZYE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for PERTZYE

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02372383 ↗	Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis	Completed	Colorado Clinical & Translational Sciences Institute	N/A	2014-10-01	The purpose of this study is to determine antimycobacterial drug pharmacokinetics (PK) and pharmacodynamics (PD) in patients with cystic fibrosis (CF) to improve treatment of nontuberculous mycobacterial (NTM) lung disease.
NCT02372383 ↗	Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis	Completed	Cystic Fibrosis Foundation	N/A	2014-10-01	The purpose of this study is to determine antimycobacterial drug pharmacokinetics (PK) and pharmacodynamics (PD) in patients with cystic fibrosis (CF) to improve treatment of nontuberculous mycobacterial (NTM) lung disease.
NCT02372383 ↗	Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis	Completed	Cystic Fibrosis Foundation Therapeutics	N/A	2014-10-01	The purpose of this study is to determine antimycobacterial drug pharmacokinetics (PK) and pharmacodynamics (PD) in patients with cystic fibrosis (CF) to improve treatment of nontuberculous mycobacterial (NTM) lung disease.
NCT02372383 ↗	Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis	Completed	University of Colorado, Denver	N/A	2014-10-01	The purpose of this study is to determine antimycobacterial drug pharmacokinetics (PK) and pharmacodynamics (PD) in patients with cystic fibrosis (CF) to improve treatment of nontuberculous mycobacterial (NTM) lung disease.
NCT02985801 ↗	PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer	Terminated	Digestive Care, Inc.	Phase 1/Phase 2	2016-12-01	Does pancreas enzyme replacement (PERT) decrease weight loss and improve quality of life in patients with unresectable pancreatic cancer?
NCT02985801 ↗	PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer	Terminated	Massimo Raimondo, M.D.	Phase 1/Phase 2	2016-12-01	Does pancreas enzyme replacement (PERT) decrease weight loss and improve quality of life in patients with unresectable pancreatic cancer?
NCT05642962 ↗	Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)	Recruiting	Memorial Sloan Kettering Cancer Center	Phase 1/Phase 2	2022-11-30	The main purpose of this study is to see how pancrelipase affects the body mass index (BMI) in people with metastatic PDAC. BMI is a measure based on a person's height and weight. Other study goals are to explore two different dosing schedules of pancrelipase and to evaluate pancrelipase in people who do not have symptoms of EPI.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for PERTZYE

Condition Name

Chart
Table

Condition Name for PERTZYE
Intervention	Trials
Pancreatic Cancer	2
Pancreatic Cancer Non-resectable	1
Pancreatic Cancer Stage IV	1
Pancreatic Carcinoma	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for PERTZYE
Intervention	Trials
Pancreatic Neoplasms	2
Cystic Fibrosis	1
Carcinoma	1
Adenocarcinoma	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for PERTZYE

Trials by Country

Map
Table

Trials by Country for PERTZYE
Location	Trials
United States	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for PERTZYE
Location	Trials
New York	1
Florida	1
Colorado	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for PERTZYE

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for PERTZYE
Clinical Trial Phase	Trials
Phase 1/Phase 2	2
N/A	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for PERTZYE
Clinical Trial Phase	Trials
Completed	1
Recruiting	1
Terminated	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for PERTZYE

Sponsor Name

Chart
Table

Sponsor Name for PERTZYE
Sponsor	Trials
Colorado Clinical & Translational Sciences Institute	1
Cystic Fibrosis Foundation	1
Cystic Fibrosis Foundation Therapeutics	1
[disabled in preview]	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for PERTZYE
Sponsor	Trials
Other	6
Industry	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.